| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.15 | 0.01 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |